My name is John T. Slevin; I have appointments at the UK Albert B. Chandler Hospital and Lexington VA Medical Center where I specialize in the evaluation of disorders of movement. My clinical research interests center on Parkinson's disease and currently include several industry-sponsored clinical drug trials of promising new anti-Parkinson medications and NIH-funded translational research. I am director of Clinical Research at the UK Parkinson’s Disease Research Center of Excellence, the UK Holsinger Parkinson’s Disease Professor of Neuroscience, and Lexington VA Center Director of the VA National Parkinson’s Disease Consortium. My research laboratory is engaged in the study of molecular mechanisms of epileptogenesis. In this capacity, I hold the Robert & Jeanne Nyere Epilepsy Research Professorship. I have authored over 200 abstracts, book chapters and research articles. A member of several professional research and clinical national societies, I am an elected Fellow of the American Academy of Neurology and member of the American Neurological Association.
Professor of Neurology; Molecular and Biomedical Pharmacology
West Virginia University, School of Medicine, Morgantown
University of Virginia Hospital, Charlottesville
Johns Hopkins Hospital, Baltimore
Certifications or Special training
American Board of Psychiatry and Neurology, Neurology
Kentucky Neuroscience Institute
First Floor, Wing C, Room B101
740 S. Limestone
Lexington KY 40536-0284
UK HealthCare accepts many forms of insurance.
See list of insurers »
Recent Publications (Five most recent publications from PubMed via an automated list based on the provider’s ID and the University of Kentucky.)
- van Horne CG, Quintero JE, Gurwell JA, Wagner RP, Slevin JT, Gerhardt GA.
Implantation of autologous peripheral nerve grafts into the substantia nigra of subjects with idiopathic Parkinson's disease treated with bilateral STN DBS: a report of safety and feasibility.
J Neurosurg. 2016 May 6;1-8.
- Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA.
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Mov Disord. 2016 Apr;31(4):530-7.
- Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, Slevin JT, Fernandez HH, Lew MF, Stein DA, Odin P, Fung VS, Klostermann F, Fasano A, Draganov PV, Schmulewitz N, Robieson WZ, Eaton S, Chatamra K, Benesh JA, Dubow J.
Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
Mov Disord. 2016 Apr;31(4):538-46.
- Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W.
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.
Parkinsonism Relat Disord. 2015 Oct;21(10):1133-44.
- Lew MF, Slevin JT, Krüger R, Martínez Castrillo JC, Chatamra K, Dubow JS, Robieson WZ, Benesh JA, Fung VS.
Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials.
Parkinsonism Relat Disord. 2015 Jul;21(7):742-8.
View this provider on PubMed